Medline (NASDAQ:MDLN) Coverage Initiated at Truist Financial

Investment analysts at Truist Financial started coverage on shares of Medline (NASDAQ:MDLN) in a research note issued to investors on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $52.00 price target on the stock. Truist Financial’s target price would suggest a potential upside of 21.35% from the company’s current price.

MDLN has been the topic of several other reports. Morgan Stanley began coverage on shares of Medline in a research report on Sunday. They set an “overweight” rating and a $48.00 target price on the stock. Mizuho started coverage on Medline in a report on Monday. They set an “outperform” rating and a $48.00 price objective on the stock. The Goldman Sachs Group began coverage on Medline in a report on Monday. They issued a “buy” rating and a $49.00 target price for the company. Sanford C. Bernstein initiated coverage on Medline in a research report on Monday. They set an “outperform” rating and a $49.00 target price for the company. Finally, Wells Fargo & Company initiated coverage on Medline in a research report on Monday. They issued an “equal weight” rating and a $42.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Medline presently has an average rating of “Moderate Buy” and a consensus target price of $46.70.

Medline Stock Up 0.3%

MDLN opened at $42.85 on Monday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $45.50.

Insider Activity at Medline

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider owned 4,806,160 shares in the company, valued at approximately $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Andrew J. Mills purchased 2,586,206 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the acquisition, the director directly owned 2,586,206 shares of the company’s stock, valued at $74,999,974. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Many major firms launched coverage with buy/overweight or strong‑buy ratings and targets clustered between $45 and $52, citing durable growth, margin expansion and a prime‑vendor advantage — this broad analyst stamp is the main driver of the rally today. TipRanks: Surge on analyst buy notes
• Positive Sentiment: Truist initiated coverage with a Buy and a $52 target (the highest among recent initiations), highlighting upside of ~20% vs. the current level — a concrete high‑target call that supports upside momentum. The Fly: Truist initiation
• Positive Sentiment: Analysts point to Medline’s scale (Jefferies highlights a ~$25bn supply‑chain footprint), vertical integration and branded‑mix shift as catalysts for margin expansion — fundamental reasons underpin many buy ratings. Yahoo Finance: Jefferies coverage
• Positive Sentiment: Medline’s IPO raised roughly $7 billion and the stock’s strong market debut has drawn Wall Street attention; post‑IPO liquidity and fresh research coverage are amplifying buying interest. NAI500: Market debut coverage
• Neutral Sentiment: Reported short interest figures are effectively zero/immaterial in the published data, so there’s no visible short‑squeeze signal backing the move — the rally appears driven by buy‑side interest and research coverage. (internal data)
• Negative Sentiment: Not all research is bullish: BNP Paribas put a neutral $38 target (implying downside), and Deutsche Bank issued a hold with a $40 target — these lower targets provide resistance for longer‑term upside and could cap gains if investors focus on valuation. Benzinga: Coverage summary
• Negative Sentiment: Wells Fargo’s equal‑weight $42 target and other neutral/hold calls (Rothschild/Rothschild Redburn) highlight mixed views on near‑term valuation — expect greater sensitivity to execution and margin guidance in coming quarters. Zacks: Analyst initiations

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.